291 related articles for article (PubMed ID: 31786688)
1. Tumor budding as a prognostic factor in pancreatic ductal adenocarcinoma.
Petrova E; Zielinski V; Bolm L; Schreiber C; Knief J; Thorns C; Bronsert P; Timme-Bronsert S; Bausch D; Perner S; Keck T; Wellner U
Virchows Arch; 2020 Apr; 476(4):561-568. PubMed ID: 31786688
[TBL] [Abstract][Full Text] [Related]
2. Tumour budding in pancreatic cancer revisited: validation of the ITBCC scoring system.
Karamitopoulou E; Wartenberg M; Zlobec I; Cibin S; Worni M; Gloor B; Lugli A
Histopathology; 2018 Jul; 73(1):137-146. PubMed ID: 29495092
[TBL] [Abstract][Full Text] [Related]
3. Tumor budding is an independent adverse prognostic factor in pancreatic ductal adenocarcinoma.
O'Connor K; Li-Chang HH; Kalloger SE; Peixoto RD; Webber DL; Owen DA; Driman DK; Kirsch R; Serra S; Scudamore CH; Renouf DJ; Schaeffer DF
Am J Surg Pathol; 2015 Apr; 39(4):472-8. PubMed ID: 25634751
[TBL] [Abstract][Full Text] [Related]
4. Evaluation and prognostic significance of tumor budding in pancreatic ductal adenocarcinomas.
Argon A; Öz Ö; Kebat TA
Indian J Pathol Microbiol; 2023; 66(1):38-43. PubMed ID: 36656208
[TBL] [Abstract][Full Text] [Related]
5. Detailed analysis of epithelial-mesenchymal transition and tumor budding identifies predictors of long-term survival in pancreatic ductal adenocarcinoma.
Kohler I; Bronsert P; Timme S; Werner M; Brabletz T; Hopt UT; Schilling O; Bausch D; Keck T; Wellner UF
J Gastroenterol Hepatol; 2015 Mar; 30 Suppl 1():78-84. PubMed ID: 25827809
[TBL] [Abstract][Full Text] [Related]
6. Tumour budding is a strong and independent prognostic factor in pancreatic cancer.
Karamitopoulou E; Zlobec I; Born D; Kondi-Pafiti A; Lykoudis P; Mellou A; Gennatas K; Gloor B; Lugli A
Eur J Cancer; 2013 Mar; 49(5):1032-9. PubMed ID: 23177090
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive histological evaluation with clinical analysis of venous invasion in pancreatic ductal adenocarcinoma: From histology to clinical implications.
Lee SJ; Sung YN; Kim SJ; Shin S; Cho H; Hruban RH; Hong SM
Pancreatology; 2020 Oct; 20(7):1486-1494. PubMed ID: 32948429
[TBL] [Abstract][Full Text] [Related]
8. Tumor budding is a prognostic factor linked to epithelial mesenchymal transition in pancreatic ductal adenocarcinoma. Study report and literature review.
Chouat E; Zehani A; Chelly I; Njima M; Maghrebi H; Bani MA; Njim L; Zakhama A; Haouet S; Kchir N
Pancreatology; 2018 Jan; 18(1):79-84. PubMed ID: 29233500
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Impact of Cell Division Cycle Associated 2 Expression on Pancreatic Ductal Adenocarcinoma.
Wang MY; Niu ZY; Gao XG; Zhou L; Liao Q; Zhao YP
Chin Med Sci J; 2016 Sep; 31(3):149-154. PubMed ID: 27733221
[TBL] [Abstract][Full Text] [Related]
10. Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma.
Lohneis P; Sinn M; Klein F; Bischoff S; Striefler JK; Wislocka L; Sinn BV; Pelzer U; Oettle H; Riess H; Denkert C; Bläker H; Jühling A
Br J Cancer; 2018 May; 118(11):1485-1491. PubMed ID: 29755112
[TBL] [Abstract][Full Text] [Related]
11. Obstructive Sleep Apnea and Pathological Characteristics of Resected Pancreatic Ductal Adenocarcinoma.
Dal Molin M; Brant A; Blackford AL; Griffin JF; Shindo K; Barkley T; Rezaee N; Hruban RH; Wolfgang CL; Goggins M
PLoS One; 2016; 11(10):e0164195. PubMed ID: 27732623
[TBL] [Abstract][Full Text] [Related]
12. Metastatic lymph node ratio as an important prognostic factor in pancreatic ductal adenocarcinoma.
Robinson SM; Rahman A; Haugk B; French JJ; Manas DM; Jaques BC; Charnley RM; White SA
Eur J Surg Oncol; 2012 Apr; 38(4):333-9. PubMed ID: 22317758
[TBL] [Abstract][Full Text] [Related]
13. Tumor budding is an independent prognostic marker in early stage oral squamous cell carcinoma: With special reference to the mode of invasion and worst pattern of invasion.
Shimizu S; Miyazaki A; Sonoda T; Koike K; Ogi K; Kobayashi JI; Kaneko T; Igarashi T; Ueda M; Dehari H; Miyakawa A; Hasegawa T; Hiratsuka H
PLoS One; 2018; 13(4):e0195451. PubMed ID: 29672550
[TBL] [Abstract][Full Text] [Related]
14. Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma.
Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Fermér C; Nilsson O; Seppänen H; Haglund C
PLoS One; 2015; 10(6):e0129012. PubMed ID: 26053486
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Factors in Resected Pancreatic Ductal Adenocarcinoma: Is Neutrophil-Lymphocyte Ratio a Useful Marker?
Merlo I; Ardiles V; Sanchez-Clariá R; Fratantoni E; de Santibañes E; Pekolj J; Mazza O; de Santibañes M
J Gastrointest Cancer; 2023 Jun; 54(2):580-588. PubMed ID: 35653056
[TBL] [Abstract][Full Text] [Related]
16. High expression of delta-like ligand 4 predicts poor prognosis after curative resection for pancreatic cancer.
Chen HT; Cai QC; Zheng JM; Man XH; Jiang H; Song B; Jin G; Zhu W; Li ZS
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S464-74. PubMed ID: 21822553
[TBL] [Abstract][Full Text] [Related]
17. Mortalin expression in pancreatic cancer and its clinical and prognostic significance.
Cui X; Li Z; Piao J; Li J; Li L; Lin Z; Jin A
Hum Pathol; 2017 Jun; 64():171-178. PubMed ID: 28412209
[TBL] [Abstract][Full Text] [Related]
18. Adenocarcinoma of the pancreas: Does prognosis depend on mode of lymph node invasion?
Buc E; Couvelard A; Kwiatkowski F; Dokmak S; Ruszniewski P; Hammel P; Belghiti J; Sauvanet A
Eur J Surg Oncol; 2014 Nov; 40(11):1578-85. PubMed ID: 24923739
[TBL] [Abstract][Full Text] [Related]
19. [Surgical therapy of pancreatic cancer - 5 years survival].
Loveček M; Skalický P; Klos D; Neoral Č; Ehrmann J; Zapletalová J; Švébišová H; Yogeswara T; Ghothim M; Vrba R; Havlík R
Rozhl Chir; 2015 Nov; 94(11):470-6. PubMed ID: 26766155
[TBL] [Abstract][Full Text] [Related]
20. PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma.
Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Kallio P; Alitalo K; Seppänen H; Haglund C
BMC Cancer; 2016 Jul; 16():472. PubMed ID: 27411302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
